ClinicalTrials.gg
CompletedNCT06480877Updated Jun 28, 2024

Effect of Aerosol From THS and Cigarette Smoke on Periodontal Tissues and Its Microbiome

An observational study in Periodontal Diseases and Dysbiosis, sponsored by Clinical Hospital Center Rijeka. Completed at 1 site in Croatia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-28.

Sponsored by Clinical Hospital Center Rijeka · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
66
Ages
18 Years and older
Sex
All
01

Study summary

Cigarette smoke has an adverse effect on the entire body as well as on the supporting apparatus of the teeth. THS (tobacco heating system) are new products on the market in which tobacco is heated and not burned like in classic cigarettes. Cigarette smoke negatively affects the immune system and vascularization, while the microbiological diversity of the dental biofilm of smokers shows a high prevalence of periodontal pathogens. The effect of THS aerosols on periodontal tissues has not been fully investigated. The research would focus on the impact of cigarette smoking and THS on periodontal tissues and compare their effects as measured by periodontal indices and subgingival microbiome analysis. Periodontal indices will give an insight into the health condition of the periodontal tissues. The microbiological profile of the subgingival areas will serve as an indicator of the effect of cigarette smoke and aerosol emitted by THS on the specific subgingival microbiome. Changes in the composition of the oral subgingival microbiome caused by environmental factors such as smoking will be analyzed using Next generation sequencing (NGS).

Read the detailed description

Periodontal diseases are multifactorial in nature, and in addition to the microbiological challenge, susceptible host and genetic background, smoking and some systemic diseases contribute to a higher incidence of periodontal diseases in such groups of people by 85%. The cause of most, if not all, diseases caused by cigarette smoking is the inhalation of toxins present in cigarette smoke. Toxins produced by burning tobacco in cigarettes contain more than 6,500 ingredients, 150 of which are toxic. Since most of these toxins are tobacco pyrolysis products, research aimed at their reduction led first to the development of electric cigarettes, and then to the THS (Tobacco Heating System) or HnB (Heat not Burn) system. There are THS, or HnB, systems from various manufacturers, but IQOS (Phillip Morris International) is one of the most widespread. It was designed as a 'healthier', i.e. less harmful, alternative for smokers of classic cigarettes. The potential of this system is that it promises less harm to human health, while at the same time instantly reducing the craving for cigarettes, and the impact on eCO (eng. exhaled CO- carbon monoxide) is minimal .

The device consists of an IQOS holder and a pocket charger. The pocket charger is used to store and charge the IQOS holder, while the holder is used to insert the HEETS tobacco insert and consume it. The principle of functioning of such cigarettes is somewhat different, but for the body's needs for nicotine, it is very similar to a classic cigarette.

Tobacco in a THS cigarette is heated up to 245 or up to 350 degrees Celsius (depending on the manufacturer), but it does not burn like in classic cigarettes, and does not produce fire, ash or smoke. By heating the tobacco in a THS cigarette, nicotine, volatile substances and glycerol are released, which create an aerosol. Such an aerosol is mainly a product of evaporation and distillation, not combustion and pyrolysis. It contains up to 90% less dangerous and potentially dangerous ingredients compared to classic cigarettes. The reduction of dangerous ingredients and the absence of smoke in such cigarettes should be accompanied by a reduction in the risk of all diseases associated with smoking traditional cigarettes. When smoking, tobacco in a classic cigarette reaches a temperature of up to 600 degrees Celsius, and in addition to fire, it also produces ash and smoke. Red and orange complexes of microorganisms, which are proven periodontal pathogenic bacteria present in people suffering from periodontal diseases, are more common in smokers than in former smokers or in those who have never smoked. Also, the prevalence of periodontal pathogens in the sulcus of healthy people who smoke is closely related to the amount of cigarettes as well as smoking status. The longer the smoking period and the greater the cigarette consumption, the greater the quantity of periodontal pathogens. Cigarette smoking affects the incidence, the course itself, but also the progression of periodontal diseases because it has a strong influence on the immune and circulatory systems. It has been proven that smoking affects the vasomotility of blood vessels, especially vasoconstriction, and that the number of blood vessels in the oral cavity is reduced in smokers, which results in weaker tissue perfusion, weaker healing, worse response to periodontal therapy, and thus the prognosis of the disease. For example, in patients suffering from aggressive periodontitis (early onset periodontitis) cigarette smoking has a direct effect on the chemotaxis and function of polymorphonuclear cells (PMN) and macrophages, a decrease in the levels of IgG and T lymphocytes , as well as NK cells. Cigarette smoke potentiates the growth of periodontopathogenic species through such modifications and manipulations of the immune system. Furthermore, cigarette smoke affects the very microbiological diversity of the surface of the buccal mucosa. Considering such an influence on mucosal microorganisms, investigators can assume that something similar can take place in the dental biofilm on the tooth surface. The literature on the harm of cigarette smoke to general health, as well as oral health, is very extensive, and there is evidence of harm to the mucous membrane of the oral cavity as well as the supporting apparatus of the teeth. It has been proven that cigarette smoke also affects the subgingival microbiological composition in healthy individuals and is responsible for the depletion of beneficial bacteria and the increase in the number of periodontal pathogens in periodontal patients. Differences in bacterial communities between smokers and non-smokers with moderate chronic periodontitis showed that bacteria of the genus Bacteroides were more common in non-smokers, and fusobacteria, fretibacteria, streptococci, and Veillonella in smokers. Also, Prevotela, Campilobacter, Aggregatibacter, Haemophilus, etc. were less common in smokers. It is also interesting that Neisseria longata is common in non-smokers, while 5 other genera of Neisseria were found in larger quantities in smokers.The effect of aerosols from THS on the cells of the oral cavity and gingiva has not been sufficiently investigated so far. Research is mainly based on the impact of such an aerosol on the epithelial cells of lung tissue or bronchi. According to one study, THS has a very similar effect on the lung parenchyma as a conventional or electric cigarette. It can increase oxidative stress, inflammation and infection and initiate epithelial-mesenchymal changes that can lead to disease. Also, THS aerosol can lead to mitochondrial dysfunction of tracheal epithelial cells leading to altered mitochondrial function that can increase airway inflammation. Examination of the cytotoxicity of THS in this study proved that it is lower compared to a classic cigarette, but higher compared to an electric cigarette. Cells exposed to THS aerosol secrete less IL-1 β and IL-6 compared to cells exposed to cigarette smoke. Another study conducted on an animal model (rat) concludes that the aerosol emitted from a single Heat Stick - HEETS (tobacco heating insert) can quickly and significantly impair the function of the endothelium of blood vessels compared to conventional cigarette smoke.

Given that the oral cavity is the first anatomical structure with which inhaled cigarette smoke or IQOS aerosol comes into contact with the vital cells of our organism, it was necessary to examine the biological impact of smoke or aerosol on human gingival fibroblasts and keratinocytes on this first interactive line. Research has proven that IQOS aerosol stimulates the proliferation of fibroblasts, prolongs and intensifies the S and G2/M phase of the cell cycle, and affects greater survival, integration and greater adhesive capabilities of keratinocytes. Most in vitro studies indicate that cigarette smoke reduces the viability, proliferation and migration of oral cells, reduces the production of inflammatory mediators, but also stops the cell cycle and initiates apoptosis. IQOS is associated with less keratinocyte apoptosis, while cigarette smoke is closely associated with high cytotoxicity and cell apoptosis.

Researches about this system and its effect on human health are lacking, and conclusions are given cautiously and dosed, calling for further investigations.

Currently, there are no available clinical or in vitro studies that are directed towards the issue of the impact of THS aerosols and cigarette smoke on periodontal tissues and that are also compared according to any parameters. Investigators hope that this research will clarify some unknowns and doubts and certainly help in better understanding the impact of this system on the dental support apparatus.

02

Conditions studied

  • Periodontal Diseases
  • Dysbiosis

Keywords

  • Periodontitis, smoking, Electronic Cigarettes, 16 s RRNA
03

In context

Periodontal Diseases

855 studies on the registry are indexed under Periodontal Diseases; 189 are open to participants now.

This study's enrollment of 66 is below the median of 100 across 300 observational studies indexed under Periodontal Diseases.

Browse Periodontal Diseases studies →

Lead sponsor

Clinical Hospital Center Rijeka is the lead sponsor of 20 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The subjects were 26-56 years old (median 38; interquartile range 34-54), and 42/66 (64%) were female.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Inclusion criteria were good general health, absence of any systemic, metabolic (diabetes), cardiovascular or any other infectious or inflammatory diseases other than periodontitis, absence of any lesions below, at or above the level of the oral mucosa, and a minimum of 20 healthy teeth. Smokers had to fulfill the criteria for smoking experience which was at least 3 years of smoking (classic cigarettes or IQOS®) and daily consumption which should not be less than 5 cigarettes or heat sticks per day.

-

Exclusion criteria

Exclusion Criteria:

  • Minors, pregnant women, subjects who use oral probiotics, subjects who have been under antibiotic therapy for the past six (6) months, subjects who use oral antiseptics based on chlorhexidine daily, subjects under immunosuppressive therapy, subjects under any medication therapy and subjects who were in previous periodontal therapy were excluded from the research.

The above listed exclusion criteria are modifiers of the supragingival and/or subgingival microbiological profile, and as such they can affect the results in the sampled microbiome. Gestational hormones during pregnancy act as growth factors for Prevotella intermedia [29]. Therapy with chlorhexidine (bisbiguanide antiseptic) preparations has bacteriostatic effect in specific doses and may also be bactericidal, while therapy with oral probiotics can increase the population and number of probiotic bacteria and stop or hinder the reproduction of pathogenic species. Some systemic diseases such as uncontrolled diabetes mellitus lead to the dominance of certain perio-pathogenic species - Capnocytophaga, P. intermedia, C. rectus, P. gingivalis and A. actinomycetemcommitans [29].

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
66 participants (actual)
Target follow-up
12 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • IQOS users

    Inclusion criteria were good general health, absence of any lesions below at or above the level of the oral mucosa, and minimum of 20 healthy teeth. Smokers had to meet the criteria for smoking experience that was at least 3 years (classic cigarette or THS) and daily consumption which should not be less than 5 cigarettes or heat sticks per day. Selected subjects were only cigarette smokers for Group I, and the same rule of selection was applied for IQOS users as Group II.

    Diagnostic Test: Taking a swab from periodontal pockets or gingival sulci

  • Cigarette smokers

    Inclusion criteria were good general health, absence of any lesions below at or above the level of the oral mucosa, and minimum of 20 healthy teeth. Smokers had to meet the criteria for smoking experience that was at least 3 years (classic cigarette or THS) and daily consumption which should not be less than 5 cigarettes or heat sticks per day. Selected subjects were only cigarette smokers for Group I, and the same rule of selection was applied for IQOS users as Group II.

    Diagnostic Test: Taking a swab from periodontal pockets or gingival sulci

  • Control group-non smokers

    Inclusion criteria were good general health, absence of any lesions below at or above the level of the oral mucosa, and minimum of 20 healthy teeth. Smokers had to meet the criteria for smoking experience that was at least 3 years (classic cigarette or THS) and daily consumption which should not be less than 5 cigarettes or heat sticks per day. Selected subjects were only cigarette smokers for Group I, and the same rule of selection was applied for IQOS users as Group II.

    Diagnostic Test: Taking a swab from periodontal pockets or gingival sulci

Interventions

  • Diagnostic testTaking a swab from periodontal pockets or gingival sulci

    Swabs for next generation sequencing were taken with paper points as described earlier.

06

What researchers measure

Primary outcomes

  1. Periodontal indices

    Three groups were formed (each N = 22): (I) subjects smoking classic cigarettes, (II) users of tobacco heating devices , and (III) subjects who have never smoked either classic cigarettes or used the THS system. Subjects were further classified into subgroups with periodontitis and without periodontitis. The procedure of each subject consisted of taking anamnestic data, clinical examination of the oral cavity, analysis of panoramic dental radiographs, and taking paper-point sample swabs from gingival sulci or periodontal pockets. Clinical examination included examination of all teeth except third molars. A millimeter graduated PCP-15 UNC periodontal probe (Hu-Friedy, Chicago, IL, USA) was used to record the following periodontal indices: probing depth , Full Mouth Bleeding Score , Full Mouth Plaque Score, gingival recession, tooth mobility, furcation defects, and clinical attachment level.

    Time frame: 1 year

Secondary outcomes

  1. results from 16S rRna sequencing

    330 paper-point samples from periodontal pockets were collected. Next-generation sequencing of 16S rRNA genes was conducted to identify the composition of subgingival microbiome

    Time frame: 1 year

07

Study locations

1 site
  • Clinical medical hospital centre Rijeka
    Rijeka, 51000, Croatia
08

References and documents

Publications

  • D'Ambrosio F, Pisano M, Amato A, Iandolo A, Caggiano M, Martina S. Periodontal and Peri-Implant Health Status in Traditional vs. Heat-Not-Burn Tobacco and Electronic Cigarettes Smokers: A Systematic Review. Dent J (Basel). 2022 Jun 8;10(6):103. doi: 10.3390/dj10060103. PubMed 35735645 ↗
  • Bizzarro S, Loos BG, Laine ML, Crielaard W, Zaura E. Subgingival microbiome in smokers and non-smokers in periodontitis: an exploratory study using traditional targeted techniques and a next-generation sequencing. J Clin Periodontol. 2013 May;40(5):483-92. doi: 10.1111/jcpe.12087. Epub 2013 Mar 13. PubMed 23489056 ↗
  • Gonzalez-Garay ML. The road from next-generation sequencing to personalized medicine. Per Med. 2014;11(5):523-544. doi: 10.2217/pme.14.34. PubMed 26000024 ↗
  • Yoshioka T, Tabuchi T. Combustible cigarettes, heated tobacco products, combined product use, and periodontal disease: A cross-sectional JASTIS study. PLoS One. 2021 Mar 30;16(3):e0248989. doi: 10.1371/journal.pone.0248989. eCollection 2021. PubMed 33784312 ↗
  • Perez-Chaparro PJ, Duarte PM, Pannuti CM, Figueiredo LC, Mestnik MJ, Goncalves CP, Faveri M, Feres M. Evaluation of human and microbial DNA content in subgingival plaque samples collected by paper points or curette. J Microbiol Methods. 2015 Apr;111:19-20. doi: 10.1016/j.mimet.2015.01.023. Epub 2015 Jan 30. PubMed 25644890 ↗
  • Shiloah J, Patters MR, Waring MB. The prevalence of pathogenic periodontal microflora in healthy young adult smokers. J Periodontol. 2000 Apr;71(4):562-7. doi: 10.1902/jop.2000.71.4.562. PubMed 10807119 ↗

Individual participant data

Plan to share: Yes — The data presented in this study are available on public repository of Faculty of Dental Medicine, University of Rijeka, Croatia. "https:/dabar.srce.hr/en/islandora/object/fdmri%3A230" ( Špalj S. Okolišni čimbenici i mikrobiološke interakcije u strukturi dentalnog biofilma:istraživački podaci.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: From 1.09.2024 till 1.9.2025

Data sharing details ↗ · dabar.srce.hr

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Jun 2023, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 28, 2024
StartActual
Jun 1, 2022
Primary completionActual
Jun 1, 2023
CompletionActual
Jun 1, 2023
Last update
Jun 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06480877
Lead sponsor
Clinical Hospital Center Rijeka
Responsible party
Sponsor
First posted
Jun 28, 2024
Start date
Jun 1, 2022
Primary completion
Jun 1, 2023
Completion
Jun 1, 2023
Last update
Jun 28, 2024

Study contacts

Stjepan Spalj, PhD
study director · Clinical medical hospital centre Rijeka

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion